NTLA FY 2016 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$16M+172.7% YoY

Gross Profit

-$15M-93.2% margin

Operating Income

-$32M-195.2% margin

Net Income

-$32M-192.0% margin

EPS (Diluted)

$-0.91

Cash Flow

Operating Cash Flow

$36M

Free Cash Flow

$30M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$299M

Total Liabilities

$89M

Stockholders' Equity

$210M

Cash & Equivalents

$273M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$16M	$6M	+172.7%
Gross Profit	-$15M	-$5M	-199.7%
Operating Income	-$32M	-$13M	-139.8%
Net Income	-$32M	-$12M	-155.2%